CCL2 and neoplasm: Currently, clinical trials of human neutralizing antibodies against CCL2 are focused on carlumab and MLN1202 that can effectively block the differentiation of monocytes to macrophages and reduce immune cell recruitment after binding to CCL2, exhibiting broad anti‐tumor effects.